R. Siegel, C. Desantis, K. Virgo, K. Stein, A. Mariotto et al., Cancer treatment and survivorship statistics, CA Cancer J Clin, vol.2012, issue.624, pp.220-241, 2012.

. Inca, La situation du cancer en France en 2010 Collection Rapports & synthèses, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, novembre 2010. [INCa. The situation in France in 2010. Reports and summaries, 2010.

A. Forsea, D. Marmol, V. De-vries, E. Bailey, E. Geller et al., Melanoma incidence and mortality in Europe: new estimates, persistent disparities, British Journal of Dermatology, vol.46, issue.5, pp.1124-1130
DOI : 10.1111/j.1365-2133.2012.11125.x

V. Gray-schopfer, C. Wellbrock, and R. Marais, Melanoma biology and new targeted therapy, Nature, vol.98, issue.7130, pp.851-857, 2007.
DOI : 10.1038/nature05661

H. Davies, G. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.417-949, 2002.
DOI : 10.1006/geno.2000.6354

P. Pollock, U. Harper, K. Hansen, L. Yudt, M. Stark et al., High frequency of BRAF mutations in nevi, Nature Genetics, vol.33, issue.1, pp.19-20, 2003.
DOI : 10.1038/nm0798-844

J. Lee, J. Choi, and Y. Kim, Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis, British Journal of Dermatology, vol.158, issue.4, pp.776-784, 2011.
DOI : 10.1111/j.1365-2133.2010.10185.x

G. Long, A. Menzies, A. Nagrial, L. Haydu, A. Hamilton et al., in Metastatic Melanoma, Journal of Clinical Oncology, vol.29, issue.10, pp.1239-1246, 2011.
DOI : 10.1200/JCO.2010.32.4327

L. Boursault, V. Haddad, B. Vergier, D. Cappellen, S. Verdon et al., Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One, p.23976959, 2013.

M. Saint-jean, G. Quereux, J. Nguyen, L. Peuvrel, A. Brocard et al., Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?, Journal of Investigative Dermatology, vol.134, issue.5, pp.1468-1470
DOI : 10.1038/jid.2013.378

J. Curtin, J. Fridlyand, T. Kageshita, H. Patel, K. Busam et al., Distinct Sets of Genetic Alterations in Melanoma, New England Journal of Medicine, vol.353, issue.20, pp.2135-2147, 2005.
DOI : 10.1056/NEJMoa050092

L. Fecher, R. Amaravadi, and K. Flaherty, The MAPK pathway in melanoma, Current Opinion in Oncology, vol.20, issue.2, pp.183-189, 2008.
DOI : 10.1097/CCO.0b013e3282f5271c

R. Amaria, K. Lewis, and A. Jimeno, Vemurafenib: The road to personalized medicine in melanoma, Drugs of Today, vol.48, issue.2, pp.109-118, 2012.
DOI : 10.1358/dot.2012.48.2.1745274

K. Flaherty, I. Puzanov, K. Kim, A. Ribas, G. Mcarthur et al., Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-819, 1002011.
DOI : 10.1056/NEJMoa1002011

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 1103782.
DOI : 10.1056/NEJMoa1103782

J. Tsai, J. Lee, W. Wang, J. Zhang, H. Cho et al., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proceedings of the National Academy of Sciences, vol.105, issue.8, pp.3041-3046, 2008.
DOI : 10.1073/pnas.0711741105

K. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe et al., Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma, New England Journal of Medicine, vol.367, issue.2, pp.107-114, 1203421.
DOI : 10.1056/NEJMoa1203421

A. Hauschild, J. Grob, L. Demidov, T. Jouary, R. Gutzmer et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, vol.380, issue.9839, pp.358-365
DOI : 10.1016/S0140-6736(12)60868-X

J. Sosman, K. Kim, L. Schuchter, R. Gonzalez, A. Pavlick et al., Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-714, 1112302.
DOI : 10.1056/NEJMoa1112302

S. Cheng, W. Koch, and L. Wu, Co-development of a companion diagnostic for targeted cancer therapy, New Biotechnology, vol.29, issue.6, pp.682-688
DOI : 10.1016/j.nbt.2012.02.002

S. Anderson, K. Bloom, D. Vallera, J. Rueschoff, C. Meldrum et al., Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma, Arch Pathol Lab Med, vol.2012, issue.13611, pp.1385-1391

H. Halait, K. Demartin, S. Shah, S. Soviero, R. Langland et al., Analytical performance of a realtime PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma, Diagn Mol Pathol, vol.2012, issue.211, pp.1-8

J. Lade-keller, K. Romer, P. Guldberg, R. Riber-hansen, L. Hansen et al., Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.70-80
DOI : 10.1016/j.jmoldx.2012.08.003

F. Nowak, J. Soria, and F. Calvo, Tumour molecular profiling for deciding therapy???the French initiative, Nature Reviews Clinical Oncology, vol.456, issue.8, pp.479-486
DOI : 10.1038/nrclinonc.2012.42

F. Nowak, F. Calvo, and J. Soria, Europe Does It Better: Molecular Testing across a National Health Care System???The French Example, American Society of Clinical Oncology Educational Book, vol.33, pp.332-339, 2013.
DOI : 10.1200/EdBook_AM.2013.33.332

E. Colomba, Z. Helias-rodzewicz, V. Deimling, A. Marin, C. Terrones et al., Detection of BRAF p.V600E Mutations in Melanomas, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.94-100
DOI : 10.1016/j.jmoldx.2012.09.001

. Inca, Les tests de génétique moléculaire pour l'accès aux therapies ciblées en 2012 Collection Bilans d'activité et d'évaluation, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2012. [INCa.Molecular genetics tests for access to targeted therapies in 2012. Collective summary of activity and evaluation, 2012.

. Inca, Synthèse de l'activité des plateformes hospitalières de génétique moléculaire des cancers en 2011 Collection Bilan d'activité et d'évaluation, ouvrage collectif édité par l'INCa, Boulogne-Billancourt, décembre 2012. [INCa. Review of the activity of hospital platforms of cancer molecular genetics in 2011. Collective summary of activity and evaluation, 2012.

M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R. Shapiro et al., Intra-and inter-tumor heterogeneity of BRAF(V600E)) mutations in primary and metastatic melanoma, PLoS One, vol.7, issue.1, p.22235286

M. Ihle, J. Fassunke, K. Konig, I. Grunewald, M. Schlaak et al., Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.2014, issue.141, p.13

K. Qu, Q. Pan, X. Zhang, L. Rodriguez, K. Zhang et al., Detection of BRAF V600 Mutations in Metastatic Melanoma, The Journal of Molecular Diagnostics, vol.15, issue.6, pp.790-795
DOI : 10.1016/j.jmoldx.2013.07.003

G. Mcarthur, P. Chapman, C. Robert, J. Larkin, J. Haanen et al., Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-355, 2014.
DOI : 10.1016/S1470-2045(14)70012-9

J. Curry, C. Torres-cabala, M. Tetzlaff, C. Bowman, and V. Prieto, Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma, Seminars in Cutaneous Medicine and Surgery, vol.31, issue.4, pp.267-273
DOI : 10.1016/j.sder.2012.07.007

M. Cousins, D. Donnell, and S. Eshleman, Impact of Mutation Type and Amplicon Characteristics on Genetic Diversity Measures Generated Using a High-Resolution Melting Diversity Assay, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.130-137
DOI : 10.1016/j.jmoldx.2012.08.008

A. Skorokhod, D. Capper, A. Von-deimling, A. Enk, and P. Helmbold, Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1, Journal of the American Academy of Dermatology, vol.67, issue.3, pp.488-91, 2012.
DOI : 10.1016/j.jaad.2012.03.022